Vance Terry 4

What Happened Vance Terry, a director of Enanta Pharmaceuticals (ENTA), received a derivative award on March 11, 2026 covering 20,000 shares. The transaction is reported as an acquisition (grant) with a transaction price of $0.00 (i.e., no cash paid at grant). This is a grant of an option-like award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-11; Form 4 filed: 2026-03-13 (appears timely).
• Amount: 20,000 shares (derivative award) at $0.00 reported transaction price.
• Vesting: Becomes exercisable monthly in substantially equal installments over one year beginning March 11, 2026; final installment vests no later than the trading day before the 2027 annual meeting (per footnote).
• Shares owned after transaction: Not specified in the filing.
• Filing timeliness: Reported within the normal Form 4 window (not indicated as late).

Context This filing documents a time-based derivative grant (options or similar) to a company director. Such grants give the holder the right to acquire shares subject to vesting; they are not immediate purchases or sales and do not by themselves indicate buying or selling sentiment. The footnote confirms monthly exercisability over one year starting at grant.